Experimental Factor Ontology (EFO) Information | |
Identifier | EFO_0005537 |
Description | An invasive breast carcinoma which is negative for expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). [NCIT: P378] | Trait category |
Cancer
|
Synonyms |
4 synonyms
|
Mapped terms |
9 mapped terms
|
Polygenic Score ID & Name | PGS Publication ID (PGP) | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants |
Ancestry distribution GWAS Dev Eval |
Scoring File (FTP Link) |
---|---|---|---|---|---|---|
PGS000216 (PRS330_TN) |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Breast cancer intrinsic-like subtype (triple negative) | triple-negative breast cancer | 330 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000216/ScoringFiles/PGS000216.txt.gz |
PGS004890 (CC-GWAS_PRS) |
PGP000620 | Sun X et al. Cancer Res (2024) |
Triple negative breast cancer versus luminal breast cancer | triple-negative breast cancer | 25 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004890/ScoringFiles/PGS004890.txt.gz |
PGS004891 (TNBC_PRS25) |
PGP000620 | Sun X et al. Cancer Res (2024) |
Triple negative breast cancer | triple-negative breast cancer | 25 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004891/ScoringFiles/PGS004891.txt.gz |
PGS004892 (TNBC_PRS41) |
PGP000620 | Sun X et al. Cancer Res (2024) |
Triple negative breast cancer | triple-negative breast cancer | 41 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004892/ScoringFiles/PGS004892.txt.gz |
PGS Performance Metric ID (PPM) |
Evaluated Score |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|---|
PPM000661 | PGS000216 (PRS330_TN) |
PSS000363| European Ancestry| 22,821 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Reported Trait: Breast cancer intrinsic-like subtype (triple negative) | OR: 1.65 [1.57, 1.73] | AUROC: 0.6358 | — | — | — |
PPM021270 | PGS004890 (CC-GWAS_PRS) |
PSS011672| Multi-ancestry (including European)| 9,868 individuals |
PGP000620 | Sun X et al. Cancer Res (2024) |
Reported Trait: Triple negative breast cancer compared to luminal-like breast cancer | — | — | Odds ratio (OR, high vs low tertile): 2.62 [1.44, 4.75] | Age at initial pathologic diagnosis of breast cancer, pathologic stage | — |
PPM021271 | PGS004891 (TNBC_PRS25) |
PSS011672| Multi-ancestry (including European)| 9,868 individuals |
PGP000620 | Sun X et al. Cancer Res (2024) |
Reported Trait: Triple negative breast cancer | — | — | Odds ratio (OR, high vs low tertile): 1.54 [0.92, 2.59] | Age at initial pathologic diagnosis of breast cancer, pathologic stage | — |
PPM021272 | PGS004892 (TNBC_PRS41) |
PSS011672| Multi-ancestry (including European)| 9,868 individuals |
PGP000620 | Sun X et al. Cancer Res (2024) |
Reported Trait: Triple negative breast cancer | — | — | Odds ratio (OR, high vs low tertile): 1.53 [0.92, 2.55] | Age at initial pathologic diagnosis of breast cancer, pathologic stage | — |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS000363 | Defined intrinsic-like breast cancer subtypes based on tumor status of ER, PR, HER2 and grade: (5) triple-negative ( ER-, PR-, HER2-). | — | [ ,
0.0 % Male samples |
— | European | — | 6 cohorts
|
Heldout subset (20%) of the BCAC consortium data |
PSS011672 | The molecular intrinsic subtypes of breast cancer were determined following the strategy of Giovanni's work using the PAM50 classifier in the TCGA-BRCA. Basal-like and luminal-like breast cancer were determined by PAM50. | — | [
|
— | European | — | TCGA | — |
PSS011672 | Triple-negative breast cancer (TNBC) was defined as ER negative, PR negative and HER2 negative. The luminal breast cancer was defined as ER and/or PR positive. | — | [
|
— | African American or Afro-Caribbean | — | AABCG | — |